Takeda Pharma FY21 Core Profit Rises

Takeda Pharmaceutical Company Limited (TKPHF.PK,TAK) reported fiscal 2021 core net profit of 663.7 million yen, an increase of 1.3% from prior year. Core earnings per share was 425 yen, up 1.2%.

Fiscal 2021 net profit was 230.1 million yen, a decline of 38.8%. Profit per share was 147 yen, down 38.9%.

Fiscal 2021 core revenue was 3.42 trillion yen, an underlying increase of 7.4%.

In FY2022, Takeda expects continued revenue growth. Core operating profit is expected to reach 1.1 trillion yen, mainly driven by business momentum.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Communications Commission or FCC has granted SpaceX Services, Inc. authorization to use its Starlink satellite internet system on vehicles in motion. SpaceX, owned by Elon Musk, is allowed to operate consumer and enterprise Ku-band Earth Stations in Motion or ESIM using frequencies allocated to the fixed satellite service. The approval would help the company to expand its services to Loud Muscle Science, LLC is recalling certain Launch Sequence products in the United States and Canada citing the presence of undeclared Tadalafil, the U.S. Food and Drug Administration said. These tainted Launch Sequence Capsule products are marketed as dietary supplements for male sexual enhancement. The U.S. Food and Drug Administration announced the intended availability of around 17 million bottles equivalent of general infant formula to be imported from New Zealand and Ireland. Under the FDA's enforcement discretion to source more infant formula to the U.S., French food company Danone SA will send 555,000 cans Aptamil Gold Plus from New Zealand.
Follow RTT